Comparison between Homocysteine, Fibrinogen, PT, PTT, INR and CRP in Male Smokers with/without Addiction to Opium

Document Type : Original Article(s)


1 Assistant Professor, Atherosclerosis Research Center, Birjand University of Medical Sciences, Birjand, Iran

2 Associate Professor, Atherosclerosis Research Center, Birjand University of Medical Sciences, Birjand, Iran

3 Associate Professor, Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran

4 Resident, Atherosclerosis Research Center, Birjand University of Medical Sciences, Birjand, Iran

5 Assistant Professor, Department of Surgery, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran


Background: Regarding the limited studies about effects of addiction on coagulation factors as a risk factor for increasing coagulation, and its relation to coronary artery disease, we decided to investigate the effect of opium on inflammatory and coagulation factors in a controlled setting.Methods: This case-control study was performed using two groups of smoking males addicted to opium (27 cases) and not addicted to opium (27 cases). After collecting demographic data, venous blood samples were gathered and sent to laboratory for measuring homocysteine, fibrinogen, prothrombin time (PT), partial thromboplastin time (PTT), International Normalized Ratio (INR), and C-reactive protein (CRP) quantity. In order to analyze the data, we used independent t-test plus Mann-Whitney test with significance level of P < 0.05.Findings: The average age in this study was 32.2 ± 6.2 in case group and 33.3 ± 6.2 in control group. Comparing case and control groups regarding age and education showed no significant difference (P = 0.598 and P = 0.848, respectively). Mean daily smoking in case group was 7.9 ± 5.4 and 8.1 ± 5.0 in control group. Mean smoking duration in case group and control group was 10.1 ± 6.5 and 9.0 ± 7.2 years, respectively. There was no significant difference between two groups regarding smoking duration (P = 0.567). Comparison of inflammatory and coagulation factors showed no significant difference except for CRP and fibrinogen for which P = 0.661 and P = 0.889, respectively. Consumption-based comparison of inflammatory and coagulation factors showed no significant difference except for PT in oral and inhaled consumptions which showed a significant difference (P = 0.035).Conclusion: Results of this study suggest that opium addiction can be an influential factor in blood parameters and can lead to inflammatory and coagulation processes complications.


  1. Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald’s heart disease: A textbook of cardiovascular medicine. 8th ed. Philadelphia, PA: Saunders; 2008. P. 1320-30.
  2. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 2007; 4(2): 143-50.
  3. Tsai JC, Kuo HT, Chiu YW, Hwang SJ, Chuang HY, Chang JM, et al. Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients. Atherosclerosis 2005; 182(1): 121-7.
  4. Gold MS, Jacob WS. Cocaine and crack: Substances of abuse. In: Lowinson J, Ruiz P, Millman RB, Langrod JG, editors. Substance abuse: A comprehensive textbook. 4th ed. Baltimore, MD: Williams and Wilkins; 2005. p. 218-251.
  5. Farahani MA, Ghaffari F, Seyed FN. Opium addiction in patients with coronary artery disease: a grounded theory study. Med J Islam Repub Iran 2015; 29: 267.
  6. Sadeghian S, Darvish S, Davoodi G, Salarifar M, Mahmoodian M, Fallah N, et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2007; 14(5): 715-7.
  7. Marmor M, Penn A, Widmer K, Levin RI, Maslansky R. Coronary artery disease and opioid use. Am J Cardiol 2004; 93(10): 1295-7.
  8. Asgary S, Sarrafzadegan N, Naderi GA, Rozbehani R. Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter? Lipids Health Dis 2008; 7: 42.
  9. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138(11): 891-7.
  10. Masoomi M, Nasri HR, Farajpour F. Comparison of plasma fibrinogen level in Opium addict men with non-addict men. J Kerman Univ Med Sci 2002; 9(1): 27-31. [In Persian].
  11. Ghazavi A, Mosayebi G, Solhi H, Rafiei M, Moazzeni SM. Serum markers of inflammation and oxidative stress in chronic opium (Taryak) smokers. Immunol Lett 2013; 153(1-2): 22-6.
  12. Moloudi A, Sabzi F, Shahhosaini E. Analysis of coagulation tests, proteins C and S, and plasma fibrinogen in addicts and non-addicts with coronary artery disease. J Kerman Univ Med Sci 2017; 17(12): 812-4. [In Persian].
  13. Mirzaeipour F, Azdaki N, Mohammadi GA, Abbasi E. The effects of opium addiction through different administration routes on inflammatory and coagulation factors. J Kerman Univ Med Sci 2013; 20(3): 292-300. [In Persian].
  14. Nemati MH, Astaneh B, Ardekani GS. Effects of opium addiction on bleeding after coronary artery bypass graft surgery: report from Iran. Gen Thorac Cardiovasc Surg 2010; 58(9): 456-60.
  15. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997; 54(Suppl 3): 32-40.
  16. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17(11): 3321-5.
  17. Kienast J. Fibrinogen and coronary heart disease. Versicherungsmedizin 1995; 47(4): 122-6. [In German].
  18. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J 1995; 16(Suppl A): 31-4.
  19. Naderi G, Asgary S, Sadeghi M, Sabetnezhad Z, Tansaz M. Comparing plasma level of CRP, factor VII, fibrinogen platelet counts, systolic and diastolic blood pressure in smokers with opium addicted. J Qazvin Univ Med Sci 2005; 9(2): 3-7. [In Persian].
  20. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118(12): 956-63.
  21. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000; 102(14): 1634-8.
  22. Hamzei MA, Ahmadi Musavi SM, Khademizadeh K. Relationship of opium dependency and stroke. Addict Health 2009; 1(1): 6-10.
  23. Tomedi LE, Bogen DL, Hanusa BH, Wisner KL, Bodnar LM. A pilot study of the nutritional status of opiate-using pregnant women on methadone maintenance therapy. Subst Use Misuse 2012; 47(3): 286-95.
  24. Zeitune MG, Bazerque E, Bazerque PM. Specific opiate effects on dextran-induced inflammation in rats. Acta Physiol Pharmacol Ther Latinoam 1991; 41(3): 349-58.
  25. van Loon JP, de Grauw JC, van Dierendonck M, L'ami JJ, Back W, van Weeren PR. Intra-articular opioid analgesia is effective in reducing pain and inflammation in an equine LPS induced synovitis model. Equine Vet J 2010; 42(5): 412-9.
  26. Perrot S, Guilbaud G, Kayser V. Effects of intraplantar morphine on paw edema and pain-related behaviour in a rat model of repeated acute inflammation. Pain 1999; 83(2): 249-57.
  27. Glattard E, Welters ID, Lavaux T, Muller AH, Laux A, Zhang D, et al. Endogenous morphine levels are increased in sepsis: a partial implication of neutrophils. PLoS One 2010; 5(1): e8791.
  28. Chadzinska M, Kolaczkowska E, Seljelid R, Plytycz B. Morphine modulation of peritoneal inflammation in Atlantic salmon and CB6 mice. J Leukoc Biol 1999; 65(5): 590-6.
  29. Krajnik M, Finlay IG, Zylicz Z. Opioids affect inflammation and the immune system. Pain Reviews 1998; 5(3): 147-52.
  30. Ditre JW, Brandon TH, Zale EL, Meagher MM. Pain, nicotine, and smoking: research findings and mechanistic considerations. Psychol Bull 2011; 137(6): 1065-93.